J Clin Invest:发现清除白血病干细胞的潜在新靶点

2018-04-03 佚名 “细胞”微信号

白血病干细胞是与白血病发生、发展和复发有关的一群细胞,在白血病干细胞上发现新的治疗靶点对于彻底治愈白血病有至关重要的意义。最近来自上海交通大学医学院的郑俊克和陈国强院士等人在白血病干细胞上发现了一个高表达的基因,并揭示了该基因参与白血病发生的重要机制。相关研究结果发表在国际学术期刊JCI上。

白血病干细胞是与白血病发生、发展和复发有关的一群细胞,在白血病干细胞上发现新的治疗靶点对于彻底治愈白血病有至关重要的意义。最近来自上海交通大学医学院的郑俊克和陈国强院士等人在白血病干细胞上发现了一个高表达的基因,并揭示了该基因参与白血病发生的重要机制。相关研究结果发表在国际学术期刊JCI上。

在这篇报道中,研究人员发现JAM3(junctional adhesion molecular 3)在小鼠和人的白血病干细胞中高水平表达,在MLL-AF9诱导的小鼠急性髓系白血病模型的系列移植过程中清除Jam3能够几乎完全阻止白血病的发生过程。相比之下,jam3缺失并不会影响小鼠造血干细胞的功能。

除此之外,研究人员还发现敲低JAM3会导致人白血病细胞系和原代白血病干细胞的增殖受到抑制。机制研究表明JAM3能够直接与LRP5发生相互作用激活下游的PDK1/AKT信号途径,随后GSK3β发生下调,β-catenin/CCND1信号途径发生激活,以维持白血病干细胞的自我更新能力和进入细胞周期的能力。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051110, encodeId=014e205111095, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 09 21:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695501, encodeId=8016169550121, content=<a href='/topic/show?id=0833e178149' target=_blank style='color:#2F92EE;'>#白血病干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71781, encryptionId=0833e178149, topicName=白血病干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=945229811725, createdName=freve, createdTime=Tue Feb 12 07:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288254, encodeId=582e1288254fd, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Apr 05 04:10:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302746, encodeId=9cc3302e462e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1cd2318604, createdName=773248030_11023610, createdTime=Wed Apr 04 19:27:53 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302382, encodeId=7429302382e6, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Tue Apr 03 13:33:06 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051110, encodeId=014e205111095, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 09 21:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695501, encodeId=8016169550121, content=<a href='/topic/show?id=0833e178149' target=_blank style='color:#2F92EE;'>#白血病干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71781, encryptionId=0833e178149, topicName=白血病干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=945229811725, createdName=freve, createdTime=Tue Feb 12 07:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288254, encodeId=582e1288254fd, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Apr 05 04:10:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302746, encodeId=9cc3302e462e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1cd2318604, createdName=773248030_11023610, createdTime=Wed Apr 04 19:27:53 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302382, encodeId=7429302382e6, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Tue Apr 03 13:33:06 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051110, encodeId=014e205111095, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 09 21:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695501, encodeId=8016169550121, content=<a href='/topic/show?id=0833e178149' target=_blank style='color:#2F92EE;'>#白血病干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71781, encryptionId=0833e178149, topicName=白血病干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=945229811725, createdName=freve, createdTime=Tue Feb 12 07:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288254, encodeId=582e1288254fd, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Apr 05 04:10:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302746, encodeId=9cc3302e462e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1cd2318604, createdName=773248030_11023610, createdTime=Wed Apr 04 19:27:53 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302382, encodeId=7429302382e6, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Tue Apr 03 13:33:06 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-05 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051110, encodeId=014e205111095, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 09 21:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695501, encodeId=8016169550121, content=<a href='/topic/show?id=0833e178149' target=_blank style='color:#2F92EE;'>#白血病干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71781, encryptionId=0833e178149, topicName=白血病干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=945229811725, createdName=freve, createdTime=Tue Feb 12 07:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288254, encodeId=582e1288254fd, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Apr 05 04:10:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302746, encodeId=9cc3302e462e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1cd2318604, createdName=773248030_11023610, createdTime=Wed Apr 04 19:27:53 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302382, encodeId=7429302382e6, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Tue Apr 03 13:33:06 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-04 773248030_11023610

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2051110, encodeId=014e205111095, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Oct 09 21:10:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1695501, encodeId=8016169550121, content=<a href='/topic/show?id=0833e178149' target=_blank style='color:#2F92EE;'>#白血病干细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71781, encryptionId=0833e178149, topicName=白血病干细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=945229811725, createdName=freve, createdTime=Tue Feb 12 07:10:00 CST 2019, time=2019-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288254, encodeId=582e1288254fd, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Apr 05 04:10:00 CST 2018, time=2018-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302746, encodeId=9cc3302e462e, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f1cd2318604, createdName=773248030_11023610, createdTime=Wed Apr 04 19:27:53 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302382, encodeId=7429302382e6, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Tue Apr 03 13:33:06 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-03 神功盖世

    0

相关资讯

盘点:梳理白血病干细胞研究重大进展

白血病是一类造血干细胞恶性克隆性疾病。克隆性白血病细胞因为增殖失控、分化障碍、凋亡受阻等机制在骨髓和其他造血组织中大量增殖累积,并浸润其他组织和器官,同时正常造血受抑制。临床可见不同程度的贫血、出血、感染发热以及肝、脾、淋巴结肿大和骨骼疼痛。据报道,我国各地区白血病的发病率在各种肿瘤中占第六位。按起病的缓急可分为急、慢性白血病。急性白血病细胞分化停滞在早期阶段,以原始及早幼细胞为主,疾病发展迅

CSC:协同响应基因调节白血病干细胞增殖和存活

白血病干细胞(LSCs)代表骨髓性白血病细胞中独特的一部分肿瘤细胞。它们细胞周期活性低,针对治疗的抵抗性强。为了更好地探究LSCs的主要特性,本研究基于不同癌基因之间的协同效应对白血病干细胞进行了综合分析。 研究者推测,被称为"协同响应基因(CRGs)"的一群基因可能调节LSCs的增长和存活。应用原代小鼠模型和人类白血病标本为研究对象,研究者发现,CRGs包括以往研究所没有发现的若干重要基因。这